Lixte Biotechnology Holdings, Inc. (LIXT), Friday announced a partnership with Swiss healthcare company Roche Holding AG (RHHBY) and the Netherlands Cancer Institute to conduct a new clinical trial for immune therapy unresponsive metastatic colon cancer.
In the trial listed as NCT06012734, Lixte will contribute its lead compound LB-100, which helps in enhancing response to immunotherapy, whereas Roche will provide atezolizumab and financial support.
Currently, LIXTE's stock is moving up 8.6 percent, to $2.8 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.